Conbercept (Research-Grade) is a research-grade biosimilar monoclonal antibody targeting Vascular endothelial growth factor A. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Vascular endothelial growth factor A, long form (VEGFA) is a ~43 kDa protein. Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A. Involved in protecting cells from hypoxia-mediated cell death. VEGFA is the therapeutic target of bevacizumab (Avastin).